Soleno Therapeutics Aktie
WKN DE: A2JSTG / ISIN: US8342032005
14.04.2025 13:32:40
|
Soleno's VYKAT XR To Treat Hyperphagia In Patients With Prader-Willi Syndrome Now Available In U.S
(RTTNews) - Soleno Therapeutics, Inc. (SLNO), Monday said VYKAT XR which was approved by the Food and Drug Administration (FDA) on March 26 to treat hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), is now commercially available in the U.S. Soleno has established a comprehensive support program, Soleno ONE, to assist patients, caregivers and healthcare providers with access to VYKAT XR.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Soleno Therapeutics Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |